Compare · ARDX vs TCDA
ARDX vs TCDA
Side-by-side comparison of Ardelyx Inc. (ARDX) and Tricida Inc. (TCDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARDX and TCDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ARDX is the larger of the two at $941.9M, about 1.7x TCDA ($550.1M).
- ARDX has hit the wire 16 times in the past 4 weeks while TCDA has been quiet.
- ARDX has more recent analyst coverage (24 ratings vs 2 for TCDA).
- Company
- Ardelyx Inc.
- Tricida Inc.
- Price
- $3.78+1.34%
- $0.10-19.25%
- Market cap
- $941.9M
- $550.1M
- 1M return
- -25.30%
- -
- 1Y return
- -38.93%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2018
- News (4w)
- 16
- 0
- Recent ratings
- 24
- 2
Ardelyx Inc.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Tricida Inc.
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest ARDX
- Chief Financial Officer Hohenleitner Susan sold $6,009 worth of shares (1,558 units at $3.86), decreasing direct ownership by 0.68% to 227,520 units (SEC Form 4) to cover withholding tax
- Officer Reilly Joseph James sold $15,358 worth of shares (3,982 units at $3.86), decreasing direct ownership by 3% to 145,854 units (SEC Form 4) (for tax liability)
- Officer Bishop John E sold $76,174 worth of shares (19,750 units at $3.86), decreasing direct ownership by 6% to 317,095 units (SEC Form 4) to cover taxes
- Chief Human Resources Officer Brady James Parker sold $58,378 worth of shares (15,136 units at $3.86), decreasing direct ownership by 6% to 245,930 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Foster Eric Duane sold $33,023 worth of shares (8,562 units at $3.86), decreasing direct ownership by 2% to 409,410 units (SEC Form 4) to cover withholding tax
- Chief Business Officer Kelliher Mike sold $29,922 worth of shares (7,758 units at $3.86), decreasing direct ownership by 2% to 349,660 units (SEC Form 4) (tax liability)
- Chief Patient Officer Williams Laura A sold $41,419 worth of shares (10,739 units at $3.86), decreasing direct ownership by 3% to 367,456 units (SEC Form 4) (tax liability)
- President & CEO Raab Michael sold $225,914 worth of shares (58,574 units at $3.86), decreasing direct ownership by 3% to 1,619,792 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Ardelyx Inc.
- SEC Form 144 filed by Ardelyx Inc.
Latest TCDA
- SEC Form EFFECT filed by Tricida Inc.
- SEC Form 15-12G filed by Tricida Inc.
- SEC Form S-8 POS filed by Tricida Inc.
- SEC Form POSASR filed by Tricida Inc.
- SEC Form POS AM filed by Tricida Inc.
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits